CVTX CV Therapeutics (MM)

PALO ALTO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (NASDAQ:CVTX) today announced that data from the Evaluation of Ranolazine In Chronic Angina (ERICA) study and two studies related to the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) will be presented at the American Heart Association (AHA) Scientific Sessions 2005. ASCOT evaluated an amplodipine plus or minus perindopril based treatment regimen compared to an atenolol plus or minus bendroflumethiazide based regimen. The AHA Scientific Sessions 2005 will take place in Dallas, TX from November 13-16, 2005. The presentations include: -- Anti-Anginal Efficacy of Ranolazine When Added to Maximal Therapy with Conventional Therapy: The Efficacy of Ranolazine in Chronic Angina Trial. Wednesday, November 16, 2005 from 3:45 p.m. to 4:00 p.m. Central Time (CT), Dallas Convention Center, C140. Oral abstract #3491. -- Differential Impact of Blood Pressure-Lowering Drugs on Central Arterial Pressure influences Clinical Outcomes - Principal Results of the Conduit Artery Function Evaluation (CAFE) Study in ASCOT. Sunday, November 13, 2005 from 3:45 p.m. to 4:00 p.m. CT, Dallas Convention Center, Arena. Late Breaking Clinical Trial. -- Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT LLA) Revisited: Interaction of Antihypertensive and Lipid Lowering Therapy. Monday, November 14, 2005 from 4:15 p.m. to 4:30 p.m. CT, Dallas Convention Center, D220. Oral abstract #730. Additional information regarding the AHA Scientific Sessions 2005 can be accessed at http://scientificsessions.org/. The ASCOT study was neither funded nor sponsored by CV Therapeutics, Inc. About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics currently has three programs in commercial or late-stage development: ACEON(R) (perindopril erbumine) Tablets, Ranexa(TM) (ranolazine) and regadenoson. CV Therapeutics also has other clinical and preclinical drug development candidates and programs. The company co-promotes ACEON(R), an ACE inhibitor, for the treatment of essential hypertension and reduction of the risk of cardiovascular mortality or non-fatal myocardial infarction in patients with stable coronary artery disease. Ranexa is being developed as a novel potential treatment for chronic angina. Regadenoson is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies. Ranexa and regadenoson have not been approved for marketing by any regulatory authorities. Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, clinical studies, regulatory review and approval, and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, early stage of development; regulatory review and approval of our products; the conduct and timing of clinical trials; the dependence on collaborative and licensing agreements; commercialization of products; market acceptance of products; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2005. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements. DATASOURCE: CV Therapeutics, Inc. CONTACT: Investors: Christopher Chai, Vice President, Treasury and Investor Relations, +1-650-384-8560, or Media: John Bluth, Senior Director, Corporate Communications, +1-650-384-8850, both of CV Therapeutics, Inc. Web site: http://www.cvt.com/

Copyright